These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes. Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119 [TBL] [Abstract][Full Text] [Related]
30. Neutralization of small RNA viruses by antibodies and antiviral agents. Rossmann MG FASEB J; 1989 Oct; 3(12):2335-43. PubMed ID: 2676677 [TBL] [Abstract][Full Text] [Related]
31. Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines. Ng Q; He F; Kwang J Viruses; 2015 Dec; 7(12):6441-57. PubMed ID: 26670245 [TBL] [Abstract][Full Text] [Related]
32. Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model. Caidi H; Miao C; Thornburg NJ; Tripp RA; Anderson LJ; Haynes LM Antiviral Res; 2018 Jun; 154():149-157. PubMed ID: 29678551 [TBL] [Abstract][Full Text] [Related]
33. Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. Prabakaran M; Prabhu N; He F; Hongliang Q; Ho HT; Qiang J; Meng T; Goutama M; Kwang J PLoS One; 2009 May; 4(5):e5672. PubMed ID: 19478856 [TBL] [Abstract][Full Text] [Related]
34. Recent progress in development of monoclonal antibodies against human cytomegalovirus. Ye X; Ku Z; Zhang N; Fu TM; An Z Curr Opin Virol; 2022 Feb; 52():166-173. PubMed ID: 34952264 [TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies for prophylactic and therapeutic use against viral infections. Both L; Banyard AC; van Dolleweerd C; Wright E; Ma JK; Fooks AR Vaccine; 2013 Mar; 31(12):1553-9. PubMed ID: 23370150 [TBL] [Abstract][Full Text] [Related]
37. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346 [TBL] [Abstract][Full Text] [Related]
38. Editorial overview: Antiviral strategies: Antiviral drug design: creating new ideas against old and new bugs. Naesens L; Zoulim F Curr Opin Virol; 2017 Jun; 24():v-vii. PubMed ID: 28743435 [No Abstract] [Full Text] [Related]
39. Virus-associated immunopathology: animal models and implications for human disease. 1. Effects of viruses on the immune system, immune-complex diseases, and antibody-mediated immunologic injury. Allison AC; Beveridge WI; Cockburn WC; East J; Goodman HC; Koprowski H; Lambert PH; van Lochem JJ; Miescher PA; Mimms CA; Notkins AL; Torrigiani G Bull World Health Organ; 1972; 47(2):257-64. PubMed ID: 4404992 [TBL] [Abstract][Full Text] [Related]
40. Harnessing immune history to combat influenza viruses. Guthmiller JJ; Wilson PC Curr Opin Immunol; 2018 Aug; 53():187-195. PubMed ID: 29890370 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]